Streetbeat News

Products Services

BDTX

Black Diamond Therapeutics presented real-world data on NSCLC patients with non-classical EGFR mutations at ESMO 2024. The study analyzed 3,276 cases, showing most patients receive frontline chemotherapy, with others treated with osimertinib or afatinib. The short treatment discontinuation time highlights an unmet need.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 8:40 am

NCNA

NuCana presented final data from its Phase 2 Nutide:701 study at the ESMO Congress. The study focused on NUC-7738 in combination with Pembrolizumab for patients with metastatic melanoma who were refractory to or had relapsed on prior PD-1 inhibitor therapy.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 8:38 am

CGEM

Cullinan Therapeutics reported updated results from its Phase 2b study of zipalertinib for non-small cell lung cancer at ESMO 2024. The study showed a 40% objective response rate and a manageable safety profile in patients with specific mutations. Enrollment for the trial was completed ahead of schedule.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 8:38 am

NVS

Novartis' Phase 3 NATALEE trial results show that adding Kisqali (Ribociclib) to endocrine therapy significantly reduces the risk of recurrence in certain early breast cancer patients by 28.5% beyond a three-year treatment period.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 8:33 am

NUVL

Nuvalent has reported positive Phase 1 data for its NSCLC programs, showing potential best-in-class profiles for zidesamtinib and NVL-655. The company is accelerating its development timeline, with pivotal data expected in 2025 and a Phase 3 trial for NVL-655 anticipated in early 2025.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 8:32 am

PFE

Pfizer announced positive results from its Phase 2 study of Ponsegromab, showing significant improvements in body weight, appetite, and muscle mass in cancer cachexia patients. The drug was safe and well-tolerated, with registration-enabling studies planned for 2025.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 8:19 am

PFE

Pfizer's BRAFTOVI + MEKTOVI demonstrates long-term efficacy in treating BRAF V600E-mutant metastatic non-small cell lung cancer, showing substantial antitumor activity and progression-free survival after three years.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 8:17 am

SOPH

SOPHiA GENETICS, in collaboration with AstraZeneca, is presenting AI-driven research at ESMO 2024. The study focuses on using machine learning to identify NSCLC patients who would benefit most from combination immunotherapy.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 8:13 am

PUBM

PubMatic has partnered with Haleon to optimize video and CTV ads globally, enhancing supply path transparency and sustainability. This collaboration aims to improve efficiency and performance for Haleon's brands like Advil, Centrum, and Tums.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 8:02 am

INCY

Incyte has unveiled promising results for its CDK2 inhibitor, INCB123667, in treating advanced solid tumors, including ovarian cancer. The data supports a pivotal trial in ovarian cancer set for 2025 and plans for combination treatments.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 7:58 am